U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H23NO2.C6H8O7
Molecular Weight 453.4828
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHOHEPTAZINE CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCOC(=O)C1(CCCN(C)CC1)C2=CC=CC=C2

InChI

InChIKey=KCVHFFSPDODYOG-UHFFFAOYSA-N
InChI=1S/C16H23NO2.C6H8O7/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-6,8-9H,3,7,10-13H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C16H23NO2
Molecular Weight 261.3593
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Ethoheptazine is an analgesic, which belongs to the proheptazine group. It was used either alone (Zactane trade name) or in combination with meprobamate and aspirin (Equagesic) for the pain relief in patients with headache or musculoskeletal disorders. Currently all mediactions containing ethoheptazine are withdrawn from the market. The exact target of ethoheptazine is unknow, but it is believed that it may have modulatory effect on opioid receptors.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
EQUAGESIC

Approved Use

Equagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache.
Primary
EQUAGESIC

Approved Use

Equagesic is possibly effective in the treatment of pain accompained by tension and anxiety in patients with musculoskeletal disease or tension headache.
Doses

Doses

DosePopulationAdverse events​
100 mg 6 times / day multiple, oral
Recommended
Dose: 100 mg, 6 times / day
Route: oral
Route: multiple
Dose: 100 mg, 6 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: F
Sources:
PubMed

PubMed

TitleDatePubMed
Mefenamic acid, chlormezanone-paracetamol, ethoheptazine-aspirin-meprobamate: a comparative study in acute low back pain.
1987-02
Fixed drug eruption masquerading as herpes simplex labialis.
1984-09-29
Determination of ethoheptazine in human post mortem material.
1983-10-14
Effects of propoxyphene, ethoheptazine, and azabicyclane on schedule-controlled responding: attenuation by pentobarbital but not naloxone.
1979
Treatment of musculoskeletal pain and associated anxiety with an ethoheptazine-aspirin-meprobamate combination (equagesic): a controlled study.
1974-09
Clinical comparison of ethoheptazine and aspirin with other analgesic combinations.
1961-03
Methods in evaluating ethoheptazine and ethoheptazine combined with aspirin.
1958-04-12
Analgesic effectiveness of orally administered ethoheptazine in man.
1957-10
Patents

Patents

Substance Class Chemical
Created
by admin
on Mon Mar 31 17:35:05 GMT 2025
Edited
by admin
on Mon Mar 31 17:35:05 GMT 2025
Record UNII
LXK8EE245D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETHOHEPTAZINE CITRATE [JAN]
Preferred Name English
ETHOHEPTAZINE CITRATE
JAN   MART.   MI   VANDF   WHO-DD  
Common Name English
ETHOHEPTAZINE CITRATE [MART.]
Common Name English
ETHOHEPTAZINE CITRATE [MI]
Common Name English
ETHYL HEXAHYDRO-1-METHYL-4-PHENYL-1H-AZEPINE-4-CARBOXYLATE CITRATE
Systematic Name English
Ethoheptazine citrate [WHO-DD]
Common Name English
ETHOHEPTAZINE CITRATE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
Code System Code Type Description
DRUG BANK
DBSALT001084
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
MERCK INDEX
m1138
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY Merck Index
CAS
6700-56-7
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
SMS_ID
100000087280
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
NCI_THESAURUS
C76841
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
RXCUI
235416
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
229-743-0
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
EVMPD
SUB02001MIG
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
ChEMBL
CHEMBL170797
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
PUBCHEM
23165
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
FDA UNII
LXK8EE245D
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
CAS
2085-42-9
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
ALTERNATIVE
EPA CompTox
DTXSID80943103
Created by admin on Mon Mar 31 17:35:05 GMT 2025 , Edited by admin on Mon Mar 31 17:35:05 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY